{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-088661","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.645349+00:00","generated_at":"2026-06-24T01:23:03.424360+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Milestone Pharma: Phase 3 RAPID PSVT trial reaches 180 events; topline data on track for mid-H2 2022","bullets":["Q2 2022 operating loss $16.8M vs income $0.7M prior year due to $15M one-time revenue from Ji Xing in 2021; cash $86.2M.","RAPID Phase 3 PSVT trial achieved target of 180 confirmed events; topline data expected mid-second half 2022.","Ji Xing enrolled first patient in Phase 3 etripamil study in China; data may support NDA in China.","NODE-302 open-label extension data showed 60.2% PSVT conversion at 30 min; 8.5% ED intervention rate.","R&D expense $10.7M in Q2 2022, up from $9.4M due to RAPID trial advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-088661","json":"https://secwatch.observer/filing/0001104659-22-088661.json","markdown":"https://secwatch.observer/filing/0001104659-22-088661.md","text":"https://secwatch.observer/filing/0001104659-22-088661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922088661/0001104659-22-088661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922088661/tm2223120d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:23:03.424360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}